Dynamic changes in soluble interleukin-2 receptor levels during treatment of Graves' disease. Correlation with disease activity.
The activation of T lymphocyte is accompanied by the release of soluble interleukin-2 receptors (sIL-2R) which can be assessed in biological fluids. A prospective study of the dynamic changes in sIL-2R levels was performed in the serum of 10 patients undergoing a medical treatment for Graves' disease. All patients received carbimazole during the study and, when necessary, L-thyroxine to compensate hypothyroidism. sIL-2R levels were measured before (M0) and after the 1st (M1), 3rd (M3) and 6th month (M6) of treatment. The levels of sIL-2R were high at M0 and M1, and decreased significantly between M1 and M3 (p = 0.03). At M0, the levels of sIL-2R were highly correlated with triiodothyronine (T3) levels (p = 0.0003), early [131I] uptake (p = 0.007) and, to a lesser degree, with anti-thyrotropin receptor antibody levels (p = 0.02). At M6, no correlation was found anymore. We conclude that sIL-2R levels are increased in patients with untreated Graves' disease. They are highly correlated with the markers of Graves' disease activity and decrease during medical treatment.
Clinique Endocrinologique, CHU de Nancy, Vandoeuvre-lès-Nancy, France.
G
G
Weryha
B
B
Gobert
J
J
Leclère
M C
MC
Béné
G
G
Faure
P
P
Hartemann
D000328:Adult; D001323:Autoantibodies / Q000097:blood; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D011989:Receptors, Thyrotropin / Q000276:immunology; D014284:Triiodothyronine / Q000097:blood
D001323:Autoantibodies; D007457:Iodine Radioisotopes; D015375:Receptors, Interleukin-2; D011989:Receptors, Thyrotropin; D014284:Triiodothyronine; D002231:Carbimazole